Final Overall Survival Analysis of Monarch 2: A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

被引：9
|
作者：
Llombart-Cussac, Antonio
Sledge, George
Toi, Masakazu
Neven, Patrick
Sohn, Joo Hyuk
Inoue, Kenichi
Pivot, Xavier
Okera, Meena
Masuda, Norikazu
Kaufman, Peter A.
Koh, Han
Grischke, Eva-Maria
Conte, PierFranco
Andre, Valerie
Bian, Yuanyuan
Shahir, Ashwin
van Hal, Gertjan
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD13-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD13-11
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Final overall survival analysis of MONARCH 2: a Phase 3 trial of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative Advanced Breast Cancer
    Grischke, E. M.
    Llombart-Cussac, A.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Conte, P.
    Andre, V
    Bian, F.
    Shahir, A.
    van Hal, G.
    Sledge Jr, G. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 30 - 30
  • [2] Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
    Binghe Xu
    Qingyuan Zhang
    Pin Zhang
    Xichun Hu
    Wei Li
    Zhongsheng Tong
    Tao Sun
    Yuee Teng
    Xinhong Wu
    Quchang Ouyang
    Xi Yan
    Jing Cheng
    Qiang Liu
    Jifeng Feng
    Xiaojia Wang
    Yongmei Yin
    Yanxia Shi
    Yueyin Pan
    Yongsheng Wang
    Weimin Xie
    Min Yan
    Yunjiang Liu
    Ping Yan
    Fei Wu
    Xiaoyu Zhu
    Jianjun Zou
    Nature Medicine, 2021, 27 : 1904 - 1909
  • [3] Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
    Xu, Binghe
    Zhang, Qingyuan
    Zhang, Pin
    Hu, Xichun
    Li, Wei
    Tong, Zhongsheng
    Sun, Tao
    Teng, Yuee
    Wu, Xinhong
    Ouyang, Quchang
    Yan, Xi
    Cheng, Jing
    Liu, Qiang
    Feng, Jifeng
    Wang, Xiaojia
    Yin, Yongmei
    Shi, Yanxia
    Pan, Yueyin
    Wang, Yongsheng
    Xie, Weimin
    Yan, Min
    Liu, Yunjiang
    Yan, Ping
    Wu, Fei
    Zhu, Xiaoyu
    Zou, Jianjun
    NATURE MEDICINE, 2021, 27 (11) : 1904 - +
  • [4] Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer
    Sun, Ryan
    Kim, Dae Hyun
    Wei, Lee-Jen
    JAMA ONCOLOGY, 2020, 6 (07) : 1121 - +
  • [5] Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy
    Kaufman, Peter A.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Grischke, Eva-Maria
    Andre, Valerie
    Stoffregen, Clemens
    Shekarriz, Sarah
    Price, Gregory L.
    Carter, Gebra Cuyun
    Sledge, George W.
    ONCOLOGIST, 2020, 25 (02): : E243 - E251
  • [6] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
    Sledge, G. W.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Grischke, E-M.
    Conte, P. F.
    Lu, Y.
    Barriga, S.
    Hurt, K.
    Frenzel, M.
    Johnston, S. R. D.
    Llombart-Cussac, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
  • [7] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
    Lim, Bora
    Potter, David A.
    Salkeni, Mohamad A.
    Silverman, Paula
    Haddad, Tufia C.
    Forget, Frederic
    Awada, Ahmad
    Canon, Jean-Luc
    Danso, Michael
    Lortholary, Alain
    Bourgeois, Hugues
    Tan-Chiu, Elizabeth
    Vincent, Sylvie
    Bahamon, Brittany
    Galinsky, Kevin J.
    Patel, Chirag
    Neuwirth, Rachel
    Leonard, E. Jane
    Diamond, Jennifer R.
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
  • [8] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
    Sledge, George W.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Conte, PierFranco
    Lu, Yi
    Barriga, Susana
    Hurt, Karla
    Frenzel, Martin
    Johnston, Stephen
    Llombart-Cussac, Antonio
    JAMA ONCOLOGY, 2020, 6 (01) : 116 - 124
  • [9] Monarch 2: Interim Overall Survival of Abemaciclib Plus Fulvestrant in Patients with HR+, HER2-Advanced Breast Cancer
    Grischke, Eva Maria
    Sledge, George W.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joo Hyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Masuda, Norikazu
    Kaufman, Peter
    Koh, Han
    Conte, Pierfranco
    Barriga, Susana
    Hurt, Karla
    Frenzel, Martin
    Johnston, Stephen
    Llombart-Cussac, Antonio
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 15 - 15
  • [10] Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
    Neven, Patrick
    Rugo, Hope S.
    Tolaney, Sara M.
    Iwata, Hiroji
    Toi, Masakazu
    Goetz, Matthew P.
    Kaufman, Peter A.
    Lu, Yi
    Haddad, Nadine
    Hurt, Karla C.
    Sledge, George W., Jr.
    BREAST CANCER RESEARCH, 2021, 23 (01)
12345